Cargando…
Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
l-Ornithine l-aspartate (LOLA), a stable salt of l-ornithine and l-aspartate, readily dissociates into its constituent amino acids that are readily absorbed by active transport, distributed, and metabolized. l-ornithine serves as an intermediary in the urea cycle in periportal hepatocytes in the liv...
Autores principales: | Kircheis, Gerald, Lüth, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416235/ https://www.ncbi.nlm.nih.gov/pubmed/30706424 http://dx.doi.org/10.1007/s40265-018-1023-2 |
Ejemplares similares
-
l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
por: Butterworth, Roger F., et al.
Publicado: (2019) -
l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease
por: Canbay, Ali, et al.
Publicado: (2019) -
Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs
por: Ahn, Jin-Ok, et al.
Publicado: (2016) -
Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
por: Safadi, Rifaat, et al.
Publicado: (2022) -
Effect of Rifaximin, Probiotics, and l-Ornithine l-Aspartate on Minimal Hepatic Encephalopathy: A Randomized Controlled Trial
por: Sharma, Kapil, et al.
Publicado: (2014)